A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation

Criterios de inclusión

• Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:
• Age ≥ 75, previous stroke
• transient ischemic attack (TIA) or Systemic Embolism (SE)
• Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%
• Diabetes mellitus or hypertension requiring pharmacological treatment